Bernadette Connaughton - 01 May 2025 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role: Director
Signature: /s/ James Oehler, Attorney-in-Fact
Issuer symbol: HALO
Transactions as of: 01 May 2025
Net transactions value: $0
Form type: 4
Filing time: 02 May 2025, 16:02:32 UTC
Previous filing: 03 Jun 2024
Next filing: 10 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Connaughton Bernadette	Director	C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO	/s/ James Oehler, Attorney-in-Fact	02 May 2025	0001662521

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HALO	Common Stock	Award	$0	+4,165	+8.9%	$0.000000	50,952	01 May 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HALO	Option to Purchase Common Stock	Award	$0	+5,750		$0.000000	5,750	01 May 2025	Common Stock	5,750	$60.03	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.
F2	Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.